Drugs / PRO044
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01037309 | Dec 2009 → May 2013 | Duchenne muscular dystrophy | BioMarin Pharmaceutical | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02329769 | Dec 2014 → Jul 2016 | Duchenne muscular dystrophy | BioMarin Pharmaceutical | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRO044 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02329769 ↗ |
| Route | Subcutaneous | “Subcutaneous injection, once a week, for five weeks” NCT01037309 ↗ |